Table 1 Study cohort’s demographic and clinical characteristics
Characteristic | N | N = 106 |
|---|---|---|
Age, mean (range) | 105 | 70.1 (47.0, 91.0) |
Unknown | 1 | |
Gender, n/N (%) | 106 | |
Female | 61/106 (58%) | |
Male | 45/106 (42%) | |
Race, n/N (%) | 105 | |
African American | 5/105 (4.8%) | |
Asian or Pacific Islander | 11/105 (10%) | |
Caucasian | 83/105 (79%) | |
Native American | 4/105 (3.8%) | |
Other | 2/105 (1.9%) | |
Unknown | 1 | |
Education (years), mean (range) | 79 | 16.05 (10.00, 21.00) |
Unknown | 27 | |
CDR score, n/N (%) | 94 | |
0 | 57/94 (61%) | |
0.5 | 31/94 (33%) | |
1 | 2/94 (2.1%) | |
2 | 2/94 (2.1%) | |
3 | 2/94 (2.1%) | |
Unknown | 12 | |
APOE genotype, n/N (%) | 106 | |
22 | 1/106 (0.9%) | |
23 | 9/106 (8.5%) | |
24 | 5/106 (4.7%) | |
33 | 52/106 (49%) | |
34 | 25/106 (24%) | |
44 | 14/106 (13%) | |
Clinical status, n/N (%) | 106 | |
NCI | 74/106 (70%) | |
MCI | 16/106 (15%) | |
AD | 16/106 (15%) | |
Homozygous Ɛ4 clinical status, n/N (%) | 14 | |
NCI | 11/14 (79%) | |
MCI | 1/14 (7.1%) | |
AD | 2/14 (14%) | |
CSF AB42 (pg/mL), median (IQR) | 90 | 280 (163, 599) |
Unknown | 16 | |
CSF total tau (pg/mL), median (IQR) | 88 | 318 (213, 455) |
Unknown | 18 | |
pTau (pg/mL), median (IQR) | 83 | 59.7 (44.8, 78.8) |
Unknown | 23 |